[go: up one dir, main page]

PE20242113A1 - Compuestos de quinolina como inhibidores de kras - Google Patents

Compuestos de quinolina como inhibidores de kras

Info

Publication number
PE20242113A1
PE20242113A1 PE2024000724A PE2024000724A PE20242113A1 PE 20242113 A1 PE20242113 A1 PE 20242113A1 PE 2024000724 A PE2024000724 A PE 2024000724A PE 2024000724 A PE2024000724 A PE 2024000724A PE 20242113 A1 PE20242113 A1 PE 20242113A1
Authority
PE
Peru
Prior art keywords
haloalkyl
alkyl
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PE2024000724A
Other languages
English (en)
Inventor
Qinda Ye
Matthew Mccammant
Rocco Policarpo
Wenyu Zhu
Jeremy Roach
Gia Hoang
Bin Hu
Gencheng Li
Robert Susick
Padmaja Polam
Fenglei Zhang
Chao Qi
xiaozhao Wang
Wenqing Yao
Alexander Sokolsky
Haolin Yin
Le Zhao
Peter Carlsen
Artem Shvartsbart
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20242113A1 publication Critical patent/PE20242113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un compuesto de formula I, o una sal aceptable farmaceuticamente del mismo, donde: Y es N o CR6; R1 se selecciona entre H, C1-3 alquilo, C1-3 haloalquilo, entre otros; R2 se selecciona entre H, C1-3 alquilo, C1-3 haloalquilo, entre otros; Cy1 se selecciona entre C3-10 cicloalquilo, heterocicloalquilo de 4-10 miembros, entre otros; R3 se selecciona entre H, C1-3 alquilo, C1-3 haloalquilo, entre otros; R5 se selecciona entre H, C1-3 alquilo, C1-3 haloalquilo, entre otros; R7 se selecciona entre H, C1-3 alquilo, C1-3 haloalquilo; entre otros. Un compuesto seleccionado es 3-(1-((1R,4R,5S)-2-Azabiciclo[2,1,1]hexan-5-il)-7-(7-cloro-3-hidroxinaftalen-1-il)-6-fluoro-2-metil-4-(1H-1,2,4-triazol-1-il)-1H-pirrolo[3,2-c]quinolin-8-il)propanonitrilo. Este compuesto de quinolina inhibe la actividad de KRAS. Tambien se refiere a la sintesis de dichos compuestos, sus compuestos intermediarios, una composicion farmaceutica que comprende dicho compuesto o una sal farmaceuticamente aceptable del mismo, y su uso en el tratamiento, prevencion o mejoramiento de enfermedades o trastornos asociados con la actividad de KRAS tales como el cancer.
PE2024000724A 2021-10-14 2022-10-13 Compuestos de quinolina como inhibidores de kras PE20242113A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163255610P 2021-10-14 2021-10-14
US202163279464P 2021-11-15 2021-11-15
US202263363270P 2022-04-20 2022-04-20
US202263368563P 2022-07-15 2022-07-15
PCT/US2022/078048 WO2023064857A1 (en) 2021-10-14 2022-10-13 Quinoline compounds as inhibitors of kras

Publications (1)

Publication Number Publication Date
PE20242113A1 true PE20242113A1 (es) 2024-10-28

Family

ID=84330780

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000724A PE20242113A1 (es) 2021-10-14 2022-10-13 Compuestos de quinolina como inhibidores de kras

Country Status (16)

Country Link
US (3) US11939328B2 (es)
EP (1) EP4415824A1 (es)
JP (1) JP2024539651A (es)
KR (1) KR20240101561A (es)
AU (1) AU2022367432A1 (es)
CA (1) CA3235146A1 (es)
CL (1) CL2024001070A1 (es)
CO (1) CO2024006030A2 (es)
CR (1) CR20240197A (es)
DO (1) DOP2024000069A (es)
EC (1) ECSP24035717A (es)
IL (1) IL312114A (es)
MX (1) MX2024004444A (es)
PE (1) PE20242113A1 (es)
TW (1) TW202322810A (es)
WO (1) WO2023064857A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras
JP7713603B2 (ja) 2022-02-09 2025-07-25 クアンタ セラピューティクス， インコーポレイテッド Ｋｒａｓモジュレーターおよびその使用
CA3257281A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics Inc PYRIMIDINE-BASED MODULATORS AND THEIR USES
WO2024015731A1 (en) * 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202446371A (zh) * 2023-04-18 2024-12-01 美商英塞特公司 ２－氮雜雙環［２．２．１］庚烷ｋｒａｓ抑制劑
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025008012A1 (en) * 2023-07-01 2025-01-09 Univerzita Palackeho V Olomouci Pyrroloquinolines and their use as tubuline assembly inhibitors
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025080593A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025080589A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Processes for preparing kras inhibitors
WO2025080585A1 (en) 2023-10-09 2025-04-17 Incyte Corporation Crystalline forms of 3-(1-(( 1 r,4r,5s)-2-azabicyclo[2.1.1 ]hexan-5-yl)-2-(( 1 r,3r,5r)-2-( cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1 h-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025129002A1 (en) * 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8928281D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2695126B1 (fr) 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
US5281608A (en) 1992-08-28 1994-01-25 American Home Products Corporation Substituted tetrahydropyrido[3',4':4,5]-pyrrolo[3,2-c]quinolines
US5612356A (en) 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
EP0632102B1 (de) 1993-06-28 1997-04-02 Bayer Ag Massefärben von Kunststoffen
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU4583599A (en) 1998-06-25 2000-01-10 Sepracor, Inc. Di- and tetra-hydroquinoline-indole antimicrobial agents, uses and compositions related thereto
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
EP1147113B1 (en) 1999-01-19 2006-06-07 Neurosearch A/S Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1142889A1 (en) 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
US7169922B2 (en) 2000-08-04 2007-01-30 Invitrogen Corporation Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7250423B2 (en) 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
JP4291696B2 (ja) 2002-01-22 2009-07-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−２−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2004253579B2 (en) 2003-07-01 2010-12-23 Biomol International L.P. Sirt1 modulators for manipulating cells/organism lifespan/stress response
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
US7592453B2 (en) 2004-04-28 2009-09-22 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
AU2006204699B2 (en) 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006079021A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
JP2008538203A (ja) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2007002867A1 (en) 2005-06-28 2007-01-04 Cv Therapeutics, Inc. Abca1 elevating compounds
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
AP2009004767A0 (en) 2006-08-07 2009-02-28 Basf Se Cubstituted azolin-2-yl-amino compounds
WO2008035356A2 (en) 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7755533B2 (en) 2006-11-01 2010-07-13 Imsar Llc Interferometric switched beam radar apparatus and method
GB0709513D0 (en) 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
WO2008079139A1 (en) 2006-12-27 2008-07-03 Cv Therapeutics, Inc. Abca1 elevating compounds
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
EP1972629A1 (en) 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2009010824A1 (en) 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
FR2934994B1 (fr) 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
KR20110095857A (ko) 2008-09-10 2011-08-25 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
JP2012506848A (ja) 2008-10-27 2012-03-22 グラクソ グループ リミテッド グルタミン酸受容体モジュレーターとしての三環式化合物
FR2939134A1 (fr) 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
FR2940285A1 (fr) 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
GB0900404D0 (en) 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds 4
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
WO2010135571A1 (en) 2009-05-20 2010-11-25 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
US20110003776A1 (en) 2009-06-03 2011-01-06 Trustees Of Boston University Tetrahydropyranonaphthyridines derivatives, pharmaceutical compositions and therapeutic treatment thereof
CA2766967A1 (en) 2009-06-30 2011-01-06 Piramal Life Sciences Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
KR101108154B1 (ko) 2009-08-10 2012-02-08 삼성모바일디스플레이주식회사 축합환 화합물 및 이를 포함한 유기층을 구비한 유기 발광 소자
WO2011031896A2 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN102115026A (zh) 2009-12-31 2011-07-06 清华大学 一维纳米结构、其制备方法及一维纳米结构作标记的方法
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
EP2571877B1 (en) 2010-05-17 2018-08-15 Boehringer Ingelheim International GmbH 1h-imidazo[4,5-c]quinolines
DE102010024335A1 (de) 2010-06-18 2011-12-22 Merck Patent Gmbh Verbindungen für elektronische Vorrichtungen
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR20130043198A (ko) 2010-07-16 2013-04-29 피라말 엔터프라이지즈 리미티드 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
WO2012011642A1 (ko) 2010-07-23 2012-01-26 고려대학교 산학협력단 염료감응 태양전지용 준고체 고분자 전해질, 그에 포함되는 정공수송물질, 및 그 전해질을 포함하는 염료감응 태양전지
MX2013002584A (es) 2010-09-07 2013-04-29 Astellas Pharma Inc Compuesto de pirazoloquinolina.
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
WO2012041227A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds for treating hepatitis c viral infection
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
HRP20161092T1 (hr) 2010-10-25 2016-10-21 G1 Therapeutics, Inc. Cdk inhibitori
CN102655637A (zh) 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信系统和组网方法
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2012154731A1 (en) 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP5742494B2 (ja) 2011-06-10 2015-07-01 住友化学株式会社 高分子化合物及びそれを用いた電子素子
JP5753027B2 (ja) 2011-08-22 2015-07-22 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
WO2013033269A1 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
CN103012397B (zh) 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
TWI562993B (en) 2011-10-07 2016-12-21 Eisai R&D Man Co Ltd Pyrazoloquinoline derivatives
MX2014004814A (es) 2011-10-21 2014-05-27 Glaxosmithkline Llc Compuestos y metodos para mejorar las respuestas inmunes innatas.
WO2013147431A1 (ko) 2012-03-28 2013-10-03 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
KR101788943B1 (ko) 2012-09-25 2017-10-20 코니카 미놀타 가부시키가이샤 유기 일렉트로루미네센스 소자, 조명 장치 및 표시 장치
JP6319097B2 (ja) 2012-12-18 2018-05-09 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置および照明装置
KR101822827B1 (ko) 2013-03-11 2018-01-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
MX359843B (es) 2013-04-05 2018-10-12 Eisai R&D Man Co Ltd Sal de derivado de pirazoloquinolina y cristal de la misma.
PE20151718A1 (es) 2013-04-05 2015-11-22 Eisai Randd Man Co Ltd Compuestos piridinilpirazoloquinolina
KR20140142088A (ko) 2013-06-03 2014-12-11 삼성디스플레이 주식회사 아릴 아민계 화합물 및 이를 포함한 유기 발광 소자
RU2663898C2 (ru) 2013-06-24 2018-08-13 Мерк Патент Гмбх Пиразольные соединения в качестве модуляторов fshr и их применение
US20160264570A1 (en) 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
JP6378106B2 (ja) 2014-04-16 2018-08-22 出光興産株式会社 化合物、有機エレクトロルミネッセンス素子および電子機器
WO2015196335A1 (en) 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof
CA2975277A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
US10251870B2 (en) 2015-03-06 2019-04-09 Stc.Unm Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
CN107835812A (zh) 2015-04-03 2018-03-23 南特生物科学股份有限公司 靶向突变体k‑ras 的组合物和方法
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
WO2016199943A1 (en) 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
CN116333138A (zh) 2015-07-30 2023-06-27 宏观基因有限公司 Pd-1结合分子和其使用方法
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017070293A1 (en) 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
CN106188138B (zh) 2015-12-02 2018-07-24 深圳市塔吉瑞生物医药有限公司 一种二氨基嘧啶化合物及包含该化合物的组合物
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
EP3558955B1 (en) 2016-12-22 2021-08-11 Amgen Inc. Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
JP7293129B2 (ja) 2017-06-01 2023-06-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｐｄｅ９阻害剤を含む医薬組成物
KR20200010220A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제
US11147803B2 (en) 2017-06-01 2021-10-19 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
CN110603040B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和多奈哌齐的痴呆治疗剂
IT201700100116A1 (it) 2017-09-07 2019-03-07 Univ Pisa Composti a struttura benzo[a]carbazolica e loro usi
US11778897B2 (en) 2017-09-20 2023-10-03 Universal Display Corporation Organic electroluminescent materials and devices
KR102552271B1 (ko) 2017-10-27 2023-07-07 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN108003153B (zh) 2017-11-24 2021-04-30 中国医学科学院肿瘤医院 含氮五元杂环并喹啉类化合物及其盐、制法、药物组合物和用途
US10597405B2 (en) 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
WO2019177971A1 (en) 2018-03-12 2019-09-19 Mavupharma, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
WO2019194481A1 (en) 2018-04-02 2019-10-10 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2019209896A1 (en) 2018-04-25 2019-10-31 Innate Tumor Immunity, Inc. Nlrp3 modulators
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
HRP20230306T1 (hr) 2018-05-11 2023-05-12 Incyte Corporation Derivati tetrahidro-imidazo[4,5-c]piridina kao pd-l1 imunomodulatori
JP7433291B2 (ja) 2018-08-16 2024-02-19 イネイト・テューマー・イミュニティ・インコーポレイテッド イミダゾ［４，５－ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター
EP3837014B1 (en) 2018-08-16 2022-10-19 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
US20210220408A1 (en) 2018-09-04 2021-07-22 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and methods of use
WO2021063346A1 (zh) 2019-09-30 2021-04-08 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
CA3163216A1 (en) 2020-01-10 2021-07-15 Incyte Corporation Tricyclic compounds as inhibitors of kras
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
EP4135844A1 (en) 2020-04-16 2023-02-22 Incyte Corporation Fused tricyclic kras inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
CN116390923B (zh) 2020-08-21 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
US12331063B2 (en) 2021-04-29 2025-06-17 Incyte Corporation Hetero-bicyclic inhibitors of KRAS
US12441727B2 (en) 2021-07-07 2025-10-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
JP2024529347A (ja) 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
JP2024534187A (ja) 2021-08-31 2024-09-18 インサイト・コーポレイション Ｋｒａｓの阻害剤としてのナフチリジン化合物
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
JP2024537824A (ja) 2021-10-01 2024-10-16 インサイト・コーポレイション ピラゾロキノリンｋｒａｓ阻害剤
PE20242113A1 (es) 2021-10-14 2024-10-28 Incyte Corp Compuestos de quinolina como inhibidores de kras

Also Published As

Publication number Publication date
ECSP24035717A (es) 2024-07-31
CL2024001070A1 (es) 2024-10-04
CO2024006030A2 (es) 2024-06-17
JP2024539651A (ja) 2024-10-29
US20230144051A1 (en) 2023-05-11
TW202322810A (zh) 2023-06-16
EP4415824A1 (en) 2024-08-21
US20240368152A1 (en) 2024-11-07
US12378243B2 (en) 2025-08-05
AU2022367432A1 (en) 2024-05-02
DOP2024000069A (es) 2024-07-15
KR20240101561A (ko) 2024-07-02
WO2023064857A1 (en) 2023-04-20
CA3235146A1 (en) 2023-04-20
MX2024004444A (es) 2024-05-08
CR20240197A (es) 2024-08-07
US20250368641A1 (en) 2025-12-04
IL312114A (en) 2024-06-01
US11939328B2 (en) 2024-03-26

Similar Documents

Publication Publication Date Title
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
PE20241127A1 (es) Compuestos triciclicos como inhibidores de kras
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
MA35090B1 (fr) Polythérapie pour les malignités hématologiques
MA50065B1 (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
AU2015256075A1 (en) Combinations of NMDAR modulating compounds
JP2015526405A (ja) 補体経路モジュレーターおよびその使用
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
WO2010056622A1 (en) TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
CL2023000670A1 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
AR119322A1 (es) Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6